Background As most of the available studies on acceptance of the coronavirus disease 2019 (COVID-19) vaccine were done prior to the development of a vaccine, this study aimed to determine the current willingness to receive the available COVID-19 vaccines in Nigeria and ascertain factors influencing its acceptance. Methodology A cross-sectional descriptive study using a paper-based questionnaire was conducted among patients aged 18 years and above, attending the General Outpatient Clinic of Federal Medical Centre, Asaba, Delta State, Nigeria (n= 366). Data were analyzed using SPSS version 26 (Armonk, NY: IBM Corp.). Univariate and bivariate analyses were conducted at an alpha level of significance set at p<0.05. Results This study comprised 366 participants, of which 56.28% were willing to take a COVID-19 vaccine if it was made available to them. Generally, it was found that participants aged <40 years (56.90%), females (56.88%), singles (57.32%), and unemployed respondents (67.44%) were more willing to receive the vaccine than others. Those who agreed that COVID-19 was not an invention by man (p=0.031; OR=1.64; 95% CI=1.05, 2.58) were more likely to receive a vaccine. Suspicion of the government's intentions about COVID-19 was a perceived barrier by participants to accepting a vaccine. Conclusion Our findings represent one of the few estimates of the acceptability of the COVID-19 vaccine in Nigeria. They can be used to guide the planning and development of future public health efforts, increasing the awareness of the COVID-19 vaccine, its acceptability, and its uptake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583703PMC
http://dx.doi.org/10.7759/cureus.29352DOI Listing

Publication Analysis

Top Keywords

covid-19 vaccine
8
attending general
8
general outpatient
8
outpatient clinic
8
vaccine hesitancy
4
hesitancy patients
4
patients attending
4
clinic tertiary
4
tertiary hospital
4
hospital southern
4

Similar Publications

Setting up a global SARS-CoV-2 surveillance system requires an understanding of how virus isolation and propagation practices, use of animal or human sera, and different neutralisation assay platforms influence assessment of SARS-CoV-2 antigenicity. In this study, with the contribution of 15 independent laboratories across all WHO regions, we carried out a controlled analysis of neutralisation assay platforms using the first WHO International Standard for antibodies to SARS-CoV-2 variants of concern (source: NIBSC). Live virus isolates (source: WHO BioHub or individual labs) or spike plasmids (individual labs) for pseudovirus production were used to perform neutralisation assays using the same serum panels.

View Article and Find Full Text PDF

The ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the continuous development of innovative vaccine strategies, especially in light of emerging viral variants that could undermine the effectiveness of existing vaccines. In this study, we developed a recombinant virus-like particle (VLP) vaccine based on the Newcastle Disease Virus (NDV) platform, displaying a stabilized prefusion form of the SARS-CoV-2 spike (S) protein. This engineered S protein includes two proline substitutions (K986P, V987P) and a mutation at the cleavage site (RRAR to QQAQ), aimed at enhancing both its stability and immunogenicity.

View Article and Find Full Text PDF

Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.

Viruses

December 2024

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement.

View Article and Find Full Text PDF

Genomic Evolution of the SARS-CoV-2 Omicron Variant in Córdoba, Argentina (2021-2022): Analysis of Uncommon and Prevalent Spike Mutations.

Viruses

December 2024

Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Córdoba X5000HUA, Argentina.

Understanding the evolutionary patterns and geographic spread of SARS-CoV-2 variants, particularly Omicron, is essential for effective public health responses. This study focused on the genomic analysis of the Omicron variant in Cordoba, Argentina from 2021 to 2022. Phylogenetic analysis revealed the dominant presence of BA.

View Article and Find Full Text PDF

In this study, we introduce a novel approach that integrates interpretability techniques from both traditional machine learning (ML) and deep neural networks (DNN) to quantify feature importance using global and local interpretation methods. Our method bridges the gap between interpretable ML models and powerful deep learning (DL) architectures, providing comprehensive insights into the key drivers behind model predictions, especially in detecting outliers within medical data. We applied this method to analyze COVID-19 pandemic data from 2020, yielding intriguing insights.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!